NEW YORK, August 1, 2017 /PRNewswire/ --
If you want a Stock Review on BDSI, BLRX, BNTC or SNGX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com has initiated coverage on BioDelivery Sciences International Inc. (NASDAQ: BDSI), BioLine Rx Ltd (NASDAQ: BLRX), Benitec Biopharma Ltd (NASDAQ: BNTC), and Soligenix Inc. (NASDAQ: SNGX). These equities operate in the Biotech space, which consists of companies engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Learn more about these stocks by downloading their comprehensive and free reports from DailyStockTracker.com member's area at:
On Monday, shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. rose 1.49%, ending the day at $3.40. The stock recorded a trading volume of 253,608 shares. The Company's shares have surged 21.43% in the last one month, 94.29% over the previous three months, and 94.29% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 27.10% and 61.19%, respectively. Moreover, shares of BioDelivery Sciences, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have a Relative Strength Index (RSI) of 66.31.
On July 28th, 2017, BioDelivery Sciences announced that it will report its Q2 2017 financial results and host a conference call and webcast at 4:30 p.m. ET on August 09th, 2017. BDSI complete research report is just a click away at:
Shares in Jerusalem, Israel headquartered BioLine Rx Ltd ended the day 7.75% higher at $1.07. A total volume of 2.12 million shares was traded, which was above their three months average volume of 396,870 shares. In the last month and the previous three months, the stock has gained 25.88% and 25.88%, respectively. Additionally, the Company's shares have advanced 16.30% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 22.90% and 9.67%, respectively. Furthermore, shares of BioLine Rx, which engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs, have an RSI of 75.57.
On July 10th, 2017, BioLine Rx announced that Genentech, a member of the Roche Group, has commenced a Phase-1b/2 study for BL-8040, in combination with atezolizumab (TECENTRIQ®), the former's anti-PDL1 cancer immunotherapy agent, evaluating the combination in metastatic pancreatic ductal adenocarcinoma. Up to forty patients are planned to be enrolled in this Phase-1b/2, multicenter, randomized, controlled, open-label study to evaluate the clinical response, safety, and tolerability, as well as multiple pharmacodynamic parameters, of BL-8040 in combination with atezolizumab. The complimentary report on BLRX can be downloaded at:
At the close of trading on Monday, shares in North Sydney, Australia headquartered Benitec Biopharma Ltd finished 5.12% higher at $2.26 with a total trading volume of 46,741 shares. The stock has advanced 20.86% in the last one month and 47.71% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 5.10% and 5.80%, respectively. Additionally, shares of Benitec Biopharma, which develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference in Australia, the UK, and the US, have an RSI of 56.17. Sign up for your complimentary research report on BNTC at:
Princeton, New Jersey headquartered Soligenix Inc.'s shares recorded a trading volume of 33,204 shares at the end of yesterday's session. The stock closed the day 3.07% higher at $2.35. The Company's shares have advanced 14.63% in the past month and 4.44% on an YTD basis. The stock is trading above its 50-day moving average by 3.16%. Additionally, shares of Soligenix, which focuses on developing and commercializing products to treat rare diseases in the US, have an RSI of 50.02.
On July 17th, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $11 per share.
On July 27th, 2017, Soligenix announced that patient enrollment has been opened for its Phase-3, multinational, randomized, double-blind, placebo-controlled study evaluating SGX942 (dusquetide) as a treatment for severe oral mucositis in patients with head and neck cancer receiving chemoradiation therapy. The Company has been working with leading oncology centers, a number of which participated in the Phase-2 study, to advance this Phase-3 clinical trial referred to as the "DOM-INNATE" study (Dusquetide treatment in Oral Mucositis - by modulating INNATE immunity). Get free access to your research report on SNGX at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA